News
The drugmaker said it would stop studying danuglipron after a participant had a possible drug-induced liver injury.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback